Allogene Therapeutics
Earl Douglas is a seasoned legal executive with extensive experience in the biotechnology and pharmaceutical sectors. Currently serving as Senior Vice President and General Counsel at Allogene Therapeutics since August 2023, Douglas has previously held significant legal roles at Applied Molecular Transport, Kiverdi, Inc., LevitasBio, and Mesoblast Limited, among others. Their expertise encompasses intellectual property, corporate governance, regulatory compliance, and commercial transactions. Douglas has contributed to the legal strategies of various companies, including overseeing IPO preparations and patent strategies for innovative biotechnological solutions. Douglas holds a Bachelor of Science in Chemical Engineering from the Massachusetts Institute of Technology and a Doctor of Law from Columbia University.
This person is not in any teams
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.